Stockreport

Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis

Spero Therapeutics, Inc.  (SPRO) 
Last spero therapeutics, inc. earnings: 3/16 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: investors.sperotherapeutics.com/overview
PDF CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and deve [Read more]